SVFC News Thursday, June 5, 2014 9:31:24 PM $SVFC
IntelliCell BioSciences announces That Merril Hoge has joined Its Board of Advisors
PR Newswire - Tue May 13, 10:45AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that Merril Hoge, former star NFL player and an on-air analyst for ESPN, has joined its Board of Advisors.
IntelliCell BioSciences Announces Positive Final Ruling Against Ironridge Global IV, LTD., and TCA Global Credit Master Fund, LP
PR Newswire - Wed May 07, 8:45AM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has received a final positive ruling in its case against Ironridge Global IV, LTD. ("Ironridge" , and TCA Global Credit Master Fund, LP ("TCA" .
IntelliCell BioSciences' Stromal Vascular Cell Technology Used For Restorative Cardiac Function With Dr. Zain Khalpey
PR Newswire - Tue Apr 29, 12:32PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous Stromal Vascular Cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it supplied its Stromal Vascular Fraction Cells, manufactured using its patented ultrasonic technology, for the restoration of cardiac function at the University of Arizona College of Medicine, Tucson in collaboration with Dr. Zain Khalpey, Division of Cardiothoracic Surgery. The autologous cells were gathered on site with Institutional Review Board approval in accordance with all applicable regulatory requirements. The case was reported in Clinical Communication to the Editor in The American Journal of Medicine Vol.127, No 5, May 2014.
inVentiv Health Clinical Engaged by IntelliCell Biosciences, a Regenerative Medicine Company, as Clinical Research Organization for Osteoarthritis IND
PR Newswire - Tue Apr 15, 9:38AM CDT
inVentiv Health Clinical, a leading global supplier of drug development services, announced today that it has been selected for an osteoarthritis Investigational New Drug Application (IND) by the innovative regenerative medicine biotechnology company IntelliCell BioSciences, Inc., (OTCQB:SVFC). IntelliCell will be studying the use of adult autologous vascular cells from blood vessels in adipose tissue to treat osteoarthritis of the knee.
IntelliCell BioSciences Has Engaged inVentiv Clinical as CRO for Osteoarthritis IND Lead by Dr. James Andrews
Marketwire - Mon Apr 14, 8:19AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stomovascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has engaged inVentiv Health Clinical as the Clinical Research Organization (CRO) for the conduct of a clinical trial in osteoarthritis of the knee under an Investigational New Drug Application (IND). Dr. James Andrews, the legendary orthopedic surgeon will be the principal investigator for the study.
IntelliCell BioSciences Announces That Dr. Steven Victor Was Thanked for His Work in Brain Trauma Research for Veterans
Marketwire - Thu Mar 27, 8:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that at the Stand For The Troops event in Washington, D.C. last Saturday, March 23, Major General John Batiste, US Army (Ret.) and Major Ben Richards, US Army (Ret.) the brain trauma veteran who received his purple heart, thanked our CEO, Steven Victor, MD for his help with brain trauma veterans.
IntelliCell BioSciences Announces That It Will Develop Investigational Clinical Protocol Studies for the Treatment of ALS With Dr. Manuel Trujillo
Marketwire - Mon Mar 24, 12:17PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it will be entering into a research collaboration with Dr. Manuel Trujillo, Clinical Psychiatry NYU Department of Psychiatry and Medical Director of the Amen Clinic, to use its unique approach to the harvest and use of autologous adipose derived stromal vascular fraction cells (SVFC) for clinical studies of ALS (Lou Gehrig's Disease).
IntelliCell BioSciences Announces It Will File an IND for Osteoarthritis of the Knee in Conjunction With the Andrews's Research and Educational Foundation
Marketwire - Mon Mar 17, 8:25AM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed consulting agreements with Dr Adam Anz and Dr Josh Hackel of the Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida. Intellicell will be filing an IND for the treatment of osteoarthritis of knee lead by Dr. James Andrews and conducted by Drs. Anz and Hackel for its Stromal Vascular Fraction Cells (SVFC).
IntelliCell BioSciences Joins Forces With Dr. James Andrews's Research and Educational Foundation
Marketwire - Wed Mar 12, 1:36PM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed a license agreement with Dr. James Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida for the installation of its cGTP Cellular Processing Lab for the manufacturing of Stromal Vascular Fraction Cells (SVFC).
IntelliCell BioSciences Raises Capital for Strategic Growth
Marketwire - Wed Mar 12, 12:59PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that it has closed on a round of financing from Yorkville Advisors, LLC.
Global Vending Machine Market 2014-2018
PR Newswire - Wed Jan 22, 9:29AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
IntelliCell Biosciences Announces it Has Received Notification That International Patents for Canada, Europe and Korea Are Filed and Pending Approvals
ACCESSWIRE - Thu Sep 19, 1:05PM CDT
NEW YORK, NY, September 19, 2013 - (ACCESSWIRE)- IntelliCell Biosciences, Inc. ("Company" (OTC Pink: SVFC) announced today that it has received notification that the Canadian Application, No. 2823123, Entitled: ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USED THEREOF has been filed.
OTC Signal Daily Stock Watch - IntelliCell BioSciences (OTC:SVFC)
WorldStockWire - Sun Sep 08, 8:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
IntelliCell BioSciences Discusses their Stem Cell Treatment Technology in Online Interview
ACCESSWIRE - Fri Jul 12, 11:32AM CDT
NEW YORK, NY, July 12, 2013 - (eTeligis via ACCESSWIRE) IntelliCell BioSciences, Inc. (OTC PINK: SVFC), a developer of novel, patented stromal vascular fraction cells (stem cells) technologies that address the regenerative, curative and preventative conditions of disease states, announces an online interview where they discuss their current SVF (stem cell) treatment technology.
Maxim Group Issues Stem Cell Sector Report on IntelliCell BioSciences Based on Treatment Process
ACCESSWIRE - Mon Jul 08, 12:01PM CDT
NEW YORK, July 08, 2013 (eTeligis via ACCESSWIRE) -- IntelliCell BioSciences, Inc. (OTCPINK: SVFC), a developer of novel, patented technology used to isolate stromal vascular fraction cells (stem cells) from adipose (fat) tissue. These cells are used to address the regenerative, curative and preventative conditions of disease, announced New York based Maxim Group has issued a research opinion on stem cell sector, and our position within the industry.
IntelliCell BioSciences Announces That Dr Zain Khalpey Has Joined Its Advisory Board
ACCESSWIRE - Mon Jun 17, 10:41AM CDT
NEW YORK, NY June 17, 2013 / -- IntelliCell BioSciences, Inc. ("Company" (OTC PINK: SVFC) announced today that Dr Zain Khalpey, MD, PhD, MRCS (Eng) Director, Heart Transplant Program & Mechanical Circulatory Support, Division of Cardiothoracic Surgery?Associate Professor of Surgery, Physiological Sciences & Biomedical Engineering, University of Arizona College of Medicine has joined the Advisory Board.
IntelliCell BioSciences Announces That Its Cellular Tissue Laboratory was inspected by FDA
PR Newswire - Fri Jun 14, 11:40AM CDT
IntelliCell BioSciences, Inc. ("Company" (OTC Pink: SVFC) announced today that on May 14, 2013 through June 2, 2013, its cellular laboratory facility underwent a thorough inspection by the FDA. The observations from the FDA inspection were provided to the company in the Form 483. The Company will respond to those observations in a timely manner. IntelliCell will take the necessary actions to address the relevant FDA observations.
IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
PR Newswire - Thu Jun 13, 11:53AM CDT
IntelliCell BioSciences, Inc. ("Company" (SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation has been made official. This technology involves an innovative mechanical method for the separation of stromal vascular fraction cells from adipose (fat) tissue, without the use of enzymes. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures. Investors can access the published patent at the US Patent website by entering the patent # 8,440,440. Link to patent website: http://patft.uspto.gov/netahtml/PTO/srchnum.htm
IntelliCell BioSciences announces That Merril Hoge has joined Its Board of Advisors
PR Newswire - Tue May 13, 10:45AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that Merril Hoge, former star NFL player and an on-air analyst for ESPN, has joined its Board of Advisors. IntelliCell BioSciences Announces Positive Final Ruling Against Ironridge Global IV, LTD., and TCA Global Credit Master Fund, LP
PR Newswire - Wed May 07, 8:45AM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has received a final positive ruling in its case against Ironridge Global IV, LTD. ("Ironridge" , and TCA Global Credit Master Fund, LP ("TCA" . IntelliCell BioSciences' Stromal Vascular Cell Technology Used For Restorative Cardiac Function With Dr. Zain Khalpey
PR Newswire - Tue Apr 29, 12:32PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous Stromal Vascular Cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it supplied its Stromal Vascular Fraction Cells, manufactured using its patented ultrasonic technology, for the restoration of cardiac function at the University of Arizona College of Medicine, Tucson in collaboration with Dr. Zain Khalpey, Division of Cardiothoracic Surgery. The autologous cells were gathered on site with Institutional Review Board approval in accordance with all applicable regulatory requirements. The case was reported in Clinical Communication to the Editor in The American Journal of Medicine Vol.127, No 5, May 2014. inVentiv Health Clinical Engaged by IntelliCell Biosciences, a Regenerative Medicine Company, as Clinical Research Organization for Osteoarthritis IND
PR Newswire - Tue Apr 15, 9:38AM CDT
inVentiv Health Clinical, a leading global supplier of drug development services, announced today that it has been selected for an osteoarthritis Investigational New Drug Application (IND) by the innovative regenerative medicine biotechnology company IntelliCell BioSciences, Inc., (OTCQB:SVFC). IntelliCell will be studying the use of adult autologous vascular cells from blood vessels in adipose tissue to treat osteoarthritis of the knee.
IntelliCell BioSciences Has Engaged inVentiv Clinical as CRO for Osteoarthritis IND Lead by Dr. James Andrews
Marketwire - Mon Apr 14, 8:19AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stomovascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has engaged inVentiv Health Clinical as the Clinical Research Organization (CRO) for the conduct of a clinical trial in osteoarthritis of the knee under an Investigational New Drug Application (IND). Dr. James Andrews, the legendary orthopedic surgeon will be the principal investigator for the study. IntelliCell BioSciences Announces That Dr. Steven Victor Was Thanked for His Work in Brain Trauma Research for Veterans
Marketwire - Thu Mar 27, 8:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that at the Stand For The Troops event in Washington, D.C. last Saturday, March 23, Major General John Batiste, US Army (Ret.) and Major Ben Richards, US Army (Ret.) the brain trauma veteran who received his purple heart, thanked our CEO, Steven Victor, MD for his help with brain trauma veterans. IntelliCell BioSciences Announces That It Will Develop Investigational Clinical Protocol Studies for the Treatment of ALS With Dr. Manuel Trujillo
Marketwire - Mon Mar 24, 12:17PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it will be entering into a research collaboration with Dr. Manuel Trujillo, Clinical Psychiatry NYU Department of Psychiatry and Medical Director of the Amen Clinic, to use its unique approach to the harvest and use of autologous adipose derived stromal vascular fraction cells (SVFC) for clinical studies of ALS (Lou Gehrig's Disease). IntelliCell BioSciences Announces It Will File an IND for Osteoarthritis of the Knee in Conjunction With the Andrews's Research and Educational Foundation
Marketwire - Mon Mar 17, 8:25AM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed consulting agreements with Dr Adam Anz and Dr Josh Hackel of the Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida. Intellicell will be filing an IND for the treatment of osteoarthritis of knee lead by Dr. James Andrews and conducted by Drs. Anz and Hackel for its Stromal Vascular Fraction Cells (SVFC). IntelliCell BioSciences Joins Forces With Dr. James Andrews's Research and Educational Foundation
Marketwire - Wed Mar 12, 1:36PM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed a license agreement with Dr. James Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida for the installation of its cGTP Cellular Processing Lab for the manufacturing of Stromal Vascular Fraction Cells (SVFC). IntelliCell BioSciences Raises Capital for Strategic Growth
Marketwire - Wed Mar 12, 12:59PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that it has closed on a round of financing from Yorkville Advisors, LLC. Global Vending Machine Market 2014-2018
PR Newswire - Wed Jan 22, 9:29AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
IntelliCell Biosciences Announces it Has Received Notification That International Patents for Canada, Europe and Korea Are Filed and Pending Approvals
ACCESSWIRE - Thu Sep 19, 1:05PM CDT
NEW YORK, NY, September 19, 2013 - (ACCESSWIRE)- IntelliCell Biosciences, Inc. ("Company"
(OTC Pink: SVFC) announced today that it has received notification that the Canadian Application, No. 2823123, Entitled: ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USED THEREOF has been filed. OTC Signal Daily Stock Watch - IntelliCell BioSciences (OTC:SVFC)
WorldStockWire - Sun Sep 08, 8:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
IntelliCell BioSciences Discusses their Stem Cell Treatment Technology in Online Interview
ACCESSWIRE - Fri Jul 12, 11:32AM CDT
NEW YORK, NY, July 12, 2013 - (eTeligis via ACCESSWIRE) IntelliCell BioSciences, Inc. (OTC PINK: SVFC), a developer of novel, patented stromal vascular fraction cells (stem cells) technologies that address the regenerative, curative and preventative conditions of disease states, announces an online interview where they discuss their current SVF (stem cell) treatment technology.
Maxim Group Issues Stem Cell Sector Report on IntelliCell BioSciences Based on Treatment Process
ACCESSWIRE - Mon Jul 08, 12:01PM CDT
NEW YORK, July 08, 2013 (eTeligis via ACCESSWIRE) -- IntelliCell BioSciences, Inc. (OTCPINK: SVFC), a developer of novel, patented technology used to isolate stromal vascular fraction cells (stem cells) from adipose (fat) tissue. These cells are used to address the regenerative, curative and preventative conditions of disease, announced New York based Maxim Group has issued a research opinion on stem cell sector, and our position within the industry.
IntelliCell BioSciences Announces That Dr Zain Khalpey Has Joined Its Advisory Board
ACCESSWIRE - Mon Jun 17, 10:41AM CDT
NEW YORK, NY June 17, 2013 / -- IntelliCell BioSciences, Inc. ("Company"
(OTC PINK: SVFC) announced today that Dr Zain Khalpey, MD, PhD, MRCS (Eng) Director, Heart Transplant Program & Mechanical Circulatory Support, Division of Cardiothoracic Surgery?Associate Professor of Surgery, Physiological Sciences & Biomedical Engineering, University of Arizona College of Medicine has joined the Advisory Board. IntelliCell BioSciences Announces That Its Cellular Tissue Laboratory was inspected by FDA
PR Newswire - Fri Jun 14, 11:40AM CDT
IntelliCell BioSciences, Inc. ("Company"
(OTC Pink: SVFC) announced today that on May 14, 2013 through June 2, 2013, its cellular laboratory facility underwent a thorough inspection by the FDA. The observations from the FDA inspection were provided to the company in the Form 483. The Company will respond to those observations in a timely manner. IntelliCell will take the necessary actions to address the relevant FDA observations. IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
PR Newswire - Thu Jun 13, 11:53AM CDT
IntelliCell BioSciences, Inc. ("Company"
(SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation has been made official. This technology involves an innovative mechanical method for the separation of stromal vascular fraction cells from adipose (fat) tissue, without the use of enzymes. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures. Investors can access the published patent at the US Patent website by entering the patent # 8,440,440. Link to patent website: http://patft.uspto.gov/netahtml/PTO/srchnum.htm 
